Biomarker for diagnosis, prediction and/or prognosis of acute heart failure and uses thereof
US10114021B2 · kind B2 · utility
0Cited by
0References
12Claims
0Family size
Assignee
Inventor
Key dates
| Filing date | Aug 19, 2016 |
| Grant date | Oct 30, 2018 |
| Priority date | — |
| Expiry date | Oct 12, 2036 |
Classification
- Technology area (CPC G)Physics
- CPC primaryG01N2800/52
- WIPO fieldMeasurement
- WIPO sectorInstruments
Abstract
The application discloses Quiescin Q6 as a new biomarker for acute heart failure. Methods for determining the quantity of Quiescin Q6 in a sample from a subject are described. The quantity of Quiescin Q6 is determined by contacting the sample with one or more binding agents capable of specifically binding to Quiescin Q6.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.